# Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

> **NCT02935712** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 44 (actual)

## Conditions studied

- Male Subjects With Type II Diabetes (T2DM)

## Interventions

- **DRUG:** AZD8601+Placebo (SAD)
- **DRUG:** AZD8601+Placebo
- **DRUG:** Placebo+Placebo

## Key facts

- **NCT ID:** NCT02935712
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-16
- **Primary completion:** 2017-08-04
- **Final completion:** 2018-01-08
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935712, "Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02935712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*